Rio Tinto (LON:RIO) Stock “Outperform” Rating Maintained at Credit Suisse; The TP is Set to GBX 4300.00; Momenta Pharmaceuticals (MNTA) Sellers Decreased By 8.91% Their Shorts

January 31, 2018 - By Adrian Mccoy

Momenta Pharmaceuticals Incorporated (NASDAQ:MNTA) had a decrease of 8.91% in short interest. MNTA’s SI was 6.45 million shares in January as released by FINRA. Its down 8.91% from 7.08M shares previously. With 545,200 avg volume, 12 days are for Momenta Pharmaceuticals Incorporated (NASDAQ:MNTA)’s short sellers to cover MNTA’s short positions. The SI to Momenta Pharmaceuticals Incorporated’s float is 10.27%. The stock increased 5.18% or $0.85 during the last trading session, reaching $17.25. About 1.75 million shares traded or 127.21% up from the average. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has risen 54.42% since January 31, 2017 and is uptrending. It has outperformed by 37.72% the S&P500.

Credit Suisse have a GBX 4300.00 PT on the stock. The PT indicates a potential upside of 8.67% from Rio Tinto (LON:RIO)‘s last price. This rating was disclosed to clients in an analyst report on Monday, 29 January.




The stock decreased 0.28% or GBX 11 during the last trading session, reaching GBX 3946. About 563,402 shares traded. Rio Tinto plc (LON:RIO) has 0.00% since January 31, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 29 analysts covering Rio Tinto PLC (LON:RIO), 18 have Buy rating, 2 Sell and 9 Hold. Therefore 62% are positive. Rio Tinto PLC has GBX 4600 highest and GBX 3 lowest target. GBX 3366.12’s average target is -14.70% below currents GBX 3946 stock price. Rio Tinto PLC had 525 analyst reports since July 23, 2015 according to SRatingsIntel. The rating was maintained by Societe Generale on Friday, November 27 with “Buy”. The company was maintained on Monday, April 11 by Liberum Capital. The firm earned “Buy” rating on Wednesday, August 12 by Jefferies. The rating was maintained by Liberum Capital with “Sell” on Wednesday, May 10. As per Monday, September 25, the company rating was maintained by Deutsche Bank. The rating was maintained by BNP Paribas with “Neutral” on Friday, October 9. Deutsche Bank maintained Rio Tinto plc (LON:RIO) on Wednesday, January 25 with “Buy” rating. The firm earned “Neutral” rating on Tuesday, November 8 by Credit Suisse. The stock has “Overweight” rating by JP Morgan on Monday, November 21. Citigroup maintained the shares of RIO in report on Thursday, August 27 with “Buy” rating.

Rio Tinto plc, a mining and metals company, finds, mines, processes, and markets mineral resources. The company has market cap of 69.13 billion GBP. The firm mines and produces aluminum products, including bauxite, alumina, and aluminum; copper, gold, silver, and molybdenum, as well as nickel; diamonds, titanium dioxide feedstocks, borates, and salt, as well as high purity iron, steel billets, metal powders, zircon, and rutile; uranium; iron ore; and thermal coal, and coking or metallurgical coal. It has a 11.5 P/E ratio. The Company’s products also comprise others, such as sulphuric acid, rhenium, lead carbonate, and selenium.

Among 12 analysts covering Momenta Pharmaceuticals (NASDAQ:MNTA), 4 have Buy rating, 2 Sell and 6 Hold. Therefore 33% are positive. Momenta Pharmaceuticals has $31 highest and $600 lowest target. $17.90’s average target is 3.77% above currents $17.25 stock price. Momenta Pharmaceuticals had 27 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) earned “Overweight” rating by Barclays Capital on Tuesday, October 11. The rating was maintained by Barclays Capital with “Equal-Weight” on Wednesday, October 4. Goldman Sachs initiated Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) on Monday, June 6 with “Neutral” rating. On Wednesday, August 2 the stock rating was maintained by Stifel Nicolaus with “Buy”. Cowen & Co maintained Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) rating on Tuesday, October 31. Cowen & Co has “Hold” rating and $15.0 target. The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has “Overweight” rating given on Friday, November 13 by JP Morgan. The rating was maintained by Barclays Capital with “Overweight” on Tuesday, January 31. Barclays Capital initiated the stock with “Equal-Weight” rating in Monday, November 23 report. Maxim Group downgraded Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) rating on Wednesday, September 7. Maxim Group has “Sell” rating and $6 target. The rating was maintained by Leerink Swann with “Outperform” on Wednesday, May 4.

Since August 2, 2017, it had 0 insider purchases, and 9 selling transactions for $1.48 million activity. Shares for $72,050 were sold by Stoner Elizabeth. Leicher Bruce sold $5,810 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) on Thursday, August 10. Another trade for 4,116 shares valued at $62,008 was made by WHEELER CRAIG A on Monday, August 21. Kaundinya Ganesh Venkataraman sold 387 shares worth $6,424.

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company has market cap of $1.32 billion. The companyÂ’s complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. It currently has negative earnings. The Company’s biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates.

Investors sentiment decreased to 1.73 in 2017 Q3. Its down 0.25, from 1.98 in 2017Q2. It turned negative, as 16 investors sold Momenta Pharmaceuticals, Inc. shares while 29 reduced holdings. 16 funds opened positions while 62 raised stakes. 70.23 million shares or 2.61% more from 68.45 million shares in 2017Q2 were reported. Pacad Investment Ltd reported 2,000 shares. California State Teachers Retirement Sys accumulated 117,464 shares. Opaleye Mngmt owns 500,000 shares. Tocqueville Asset Mgmt Limited Partnership holds 280,488 shares or 0.06% of its portfolio. Goldman Sachs Grp Inc has 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Wells Fargo & Mn has 219,520 shares. Whittier Trust owns 100,428 shares for 0.07% of their portfolio. Ls Invest Advsr Ltd Co reported 5,821 shares. Vanguard Gp holds 0.01% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 6.59M shares. The Massachusetts-based Loring Wolcott Coolidge Fiduciary Advsrs Llp Ma has invested 0% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Invesco holds 0.02% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 3.51M shares. Louisiana State Employees Retirement Systems reported 30,900 shares. Envestnet Asset Inc, a Illinois-based fund reported 14,577 shares. Jacobs Levy Equity Mngmt accumulated 188,919 shares. California-based Palo Alto Invsts has invested 1.4% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: